Abstract:RRP is caused by HPV infection of the aerodigestive tract that significantly impacts quality‐of‐life including the ability to communicate and breathe. This study aims to determine whether rationale exists for combination therapeutic approaches using VEGF inhibitors and/or immune checkpoint blockade. Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Objectives Recurrent respiratory papillomatosis (RRP) is caused by human papilloma virus (HPV) infection of the aerodigestive tract that significantly impacts quality‐of‐life including the ability to communicate and breathe. Treatment was traditionally limited to serial ablative procedures in the O.R. with possible local adjuvant therapy, but new systemic therapies, such as Vascular endothelial growth factor (VEGF) inhibitors, are showing significant promise. This study aims to determine whether rationale exists for combination therapeutic approaches using VEGF inhibitors and/or immune checkpoint blockade. Methods Using fresh specimens from the O.R., we performed flow cytometry on papilloma, normal adjacent tissue, and blood. Papilloma and surrounding tissue were examined for expression of PD‐L1, PD‐L2, Galectin‐9, VEGFR2, and VEGFR3. CD8+ and CD4+ T cells were assayed for expression of PD‐1, TIGIT, LAG3, and TIM3. Results Our data shows that papilloma tissue exhibits significantly higher levels of PD‐L1 and PD‐L2 compared to adjacent tissue. Elevated levels of the VEGF receptor VEGFR3 were also observed in papilloma tissue. When examining T cells within the papilloma, elevated PD‐1 and TIGIT expression was observed on CD8+ T cells, while levels of PD‐1, TIGIT, and TIM3 were elevated on CD4+ T cells compared to PBMCs. Heterogenous marker expression was observed between individuals. Conclusions Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Laryngoscope, 2024

Quality of Life in Recurrent Respiratory Papillomatosis Patients after Vocal Fold Surgery: An In-Depth Exploration

Current Practice, Safety and Efficacy of Interventions for Recurrent Respiratory Papillomatosis: Evidence From a UK Registry

Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis

Recurrent respiratory papillomatosis: comparing in-office and operating room treatments

Longitudinal Patient-Reported Voice Quality in Early-Stage Glottic Cancer

Analysis of Postsurgical Health-Related Quality of Life and Quality of Voice of Patients with Laryngeal Carcinoma.

Measuring Quality of Life in Pediatric Paradoxical Vocal Fold Motion Using the SF-36v2

Voice-Related Quality of Life in Post-Laryngectomy Rehabilitation: Tracheoesophageal Fistula’s Wellness

Adjuvant Intralesional Bevacizumab in Pediatric and Adult Populations With Recurrent Respiratory Papillomatosis: A Systematic Review

A Descriptive Study of Quality of Life Following Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma

Associations between hypopharyngeal defect closure and quality of life in long‐term total laryngectomy survivors

Prospective Outcomes After Serial Platelet-Rich Plasma (PRP) Injection in Vocal Fold Scar and Sulcus

Quality-of-Life Outcomes Following Endoscopic Resection of Sinonasal Inverted Papilloma

Successful Bevacizumab Therapy in a 25-Year-Old Patient with Recurrent Respiratory Papillomatosis

Effectiveness of combined approach to recurrent respiratory papillomatosis (RRP)

Recurrence of benign phonotraumatic vocal fold lesions after microlaryngoscopy

Clinical study of the influence of laryngopharyngeal reflux on quality of life in patients with dysphonia

Voice quality after open partial horizontal laryngectomy vs. total laryngectomy with voice prosthesis: a comparative study

VEGF as a Key Actor in Recurrent Respiratory Papillomatosis: A Narrative Review

Human papilloma virus (HPV) vaccination is associated with reduced number of surgical treatments, an observational study on recurrent respiratory papillomatosis in Northern Sweden

Evaluating the efficacy and safety of intralesional bevacizumab in the treatment of recurrent respiratory papillomatosis: A systematic review